Literature DB >> 30367136

The expanding role of implantable devices to monitor heart failure and pulmonary hypertension.

Magdi H Yacoub1, Christopher McLeod2.   

Abstract

The epidemics of heart failure and, to a lesser extent, of pulmonary arterial hypertension continue unabated worldwide and are extremely costly in terms of loss of life and earnings, as well as the burden of health-care expenditure due to repeated hospitalization. The effectiveness of newly discovered therapies for the two conditions depends on their timely application. To date, symptoms have been used to guide the application and timing of therapy. Compelling evidence now exists that symptoms are preceded by several metabolic and haemodynamic changes, particularly a rise in intravascular pressures during exercise. These observations have stimulated the development of several implantable devices for the detection of impending unstable heart failure or pulmonary arterial hypertension, necessitating admission to hospital. In this Review, we summarize the rationale for monitoring patients with heart failure or pulmonary arterial hypertension, the transition from noninvasive to implantable devices and the current and anticipated clinical uses of these devices.

Entities:  

Mesh:

Year:  2018        PMID: 30367136     DOI: 10.1038/s41569-018-0103-z

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  4 in total

Review 1.  Recent advances in bioelectronics chemistry.

Authors:  Yin Fang; Lingyuan Meng; Aleksander Prominski; Erik N Schaumann; Matthew Seebald; Bozhi Tian
Journal:  Chem Soc Rev       Date:  2020-07-16       Impact factor: 54.564

Review 2.  Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.

Authors:  Jonathan M Kalman; Sergio Lavandero; Felix Mahfoud; Matthias Nahrendorf; Magdi H Yacoub; Dong Zhao
Journal:  Nat Rev Cardiol       Date:  2019-09-30       Impact factor: 32.419

3.  Remote invasive monitoring of pulmonary artery pressures in heart failure patients: Initial experience in Portugal in the context of the Covid-19 pandemic.

Authors:  Vera Vaz Ferreira; Tiago Pereira-da-Silva; Duarte Cacela; Rui Cruz Ferreira
Journal:  Rev Port Cardiol       Date:  2021-11-22       Impact factor: 1.651

4.  DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment.

Authors:  Zerong Li; Wenmei Qiao; Chenghao Wang; Heqiao Wang; Mengchao Ma; Xinyu Han; Jingling Tang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.